Meeting
2021 Gastrointestinal Cancers Symposium
Incidence and patterns of secondary malignancies in patients with neuroendocrine neoplasms: A SEER database analysis.
Authors
Meena Sadaps
Cleveland Clinic, Cleveland, OH
Meena Sadaps , Neal Mehta , Hong Li , Bassam N. Estfan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Neuroendocrine/Carcinoid
Track
Neuroendocrine/Carcinoid
Sub Track
Other
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 374)
DOI
10.1200/JCO.2021.39.3_suppl.374
Abstract #
374
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
First Author: Michael J. Demeure
Poster
2023 ASCO Gastrointestinal Cancers Symposium
ETCTN 10450: A phase I trial of peposertib and lutetium 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Randomized, parallel arm, phase II study of telotristat (Xermelo) in combination with lutetium Lu 177 dotatate (Lutathera) in well-differentiated neuroendocrine tumors (NETs).
First Author: Aman Chauhan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
First Author: Stijn Hentzen